The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

Yıl: 2023 Cilt: 24 Sayı: 2 Sayfa Aralığı: 216 - 220 Metin Dili: İngilizce DOI: 10.4274/imj.galenos.2023.98370 İndeks Tarihi: 06-06-2023

The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

Öz:
Introduction: Chronic graft-versus host disease (GVHD) is a serious complication that develops in 35-50% of patients in the late period after allogeneic hematopoetic stem cell transplantation. About half of the patients are resistant to corticosteroids, which is the first-line treatment of chronic GVHD, and therefore new treatment options that can be effective in chronic GVHD are needed. In the present study, we aimed to share our experience with the use of ibrutinib therapy in patients with steroid-resistant chronic GVHD who have previously received multiple lines of systemic therapy. Methods: The characteristics and clinical outcomes of steroid-resistant chronic patients with GVHD receiving ibrutinib were retrospectively reviewed. Results: A total of 10 steroid resi-stant chronic patients with GVHD who received ibrutinib was included. While 50% of the patients had more than one organ involvement, 50% had a single organ involvement. The most commonly affected organs were the skin and liver. The patients received a median of three lines of systemic therapy before ibrutinib. After a median of 210 days of ibrutinib usage, the complete response rate of patients was 40% and the partial response rate was 40%. Corticosteroids were completely discontinued in 30% of patients after ibrutinib were initiated. Before ibrutinib, patients were given a median of 0.3 mg/kg methylprednisolone. The median methylprednisolone dose after ibrutinib was 0.03 mg/kg. Conclusion: Ibrutinib therapy causes a quite high overall response in steroid resistant chronic patients with GVHD and appears to be a good option in these patients.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Trajkovska I, Georgievski B, Cevreska L, Gacovski A, Hasan T, Nedeska-Minova N. Early and Late Complications in Patients with Allogeneic Transplantation of Hematopoietic Stem Cell–Case Report. Open Access Maced J Med Sci 2017; 5: 340.
  • 2. Atilla PA, Atilla E, Toprak SK, Demirer T. Non-infectious early complications of allogeneic stem cell transplantations. UHOD 2016; 29: 239-50.
  • 3. Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH, et al. Transplantation- related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant 2013; 19: 552-61.
  • 4. Atilla E, Atilla PA, Toprak SK, Demirer T. A review of late complications of allogeneic hematopoietic stem cell transplantations. Clinical transplantation 2017; 31: e13062.
  • 5. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol 2011; 29: 2230.
  • 6. Bhatia S, Francisco L, Carter A, Sun CL, Baker KS, Gurney JG, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood 2007; 110: 3784-92.
  • 7. Sarantopoulos S, Cardones AR, Sullivan KM. How I treat refractory chronic graft-versus-host disease. Blood 2019; 133: 1191-200.
  • 8. Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 2012; 120: 2545-52.
  • 9. Csanadi M, Agh T, Tordai A, Webb T, Jeyakumaran D, Sengupta N, et al. A systematic literature review of incidence, mortality, and relapse of patients diagnosed with chronic graft versus host disease. Expert Rev Hematol 2019; 12: 311-23.
  • 10. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; 7: e157-e67.
  • 11. Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, et al. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2020; 18: 599-634.
  • 12. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-56.
  • 13. Lee SJ, Wolff D, Kitko C, Koreth J, Inamoto Y, Jagasia M, et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant2015; 21: 984-99.
  • 14. Lee SJ, Kim HT, Ho VT, Cutler C, Alyea EP, Soiffer RJ, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 305-10.
  • 15. Clavert A, Chevallier P, Guillaume T, Delaunay J, Le Gouill S, Mahe B, et al. Safety and efficacy of rituximab in steroid-refractory chronic GVHD. Bone Marrow Transplant 2013; 48: 734-6.
  • 16. Pidala J, Kim J, Roman-Diaz J, Shapiro J, Nishihori T, Bookout R, et al. Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. Ann Transplant 2010; 15: 21-9.
  • 17. Lopez F, Parker P, Nademanee A, Rodriguez R, Al-Kadhimi Z, Bhatia R, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus- host disease. Biol Blood Marrow Transplant 2005; 11: 307-13.
  • 18. Escamilla Gómez V, García-Gutiérrez V, López Corral L, García Cadenas I, Pérez Martínez A, Márquez Malaver FJ, et al. Ruxolitinib in refractory acute and chronic graft-versus-host disease: a multicenter survey study. Bone Marrow Transplant 2020; 55: 641-8.
  • 19. Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Balsalobre P, et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft- versus-host disease. Biol Blood Marrow Transplant 2007; 13: 701-6.
  • 20. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N,et al. A randomized phase II crossover study of imatinib or rituximab for cutaneous sclerosis after hematopoietic cell transplantation. Clin Cancer Res 2016; 22: 319-27.
  • 21. Couriel DR, Saliba R, Escalón MP, Hsu Y, Ghosh S, Ippoliti C,et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft versus host disease. Br J Hematol 2005; 130: 409-17.
  • 22. Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolaños-Meade J, et al. Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. J Clin Oncol 2007; 25: 4255-61.
  • 23. Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 2014; 124: 4867-76.
  • 24. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 2017; 130: 2243-50.
  • 25. Teusink-Cross A, Davies SM, Grimley MS, Chandra S, Flannery A, Dandoy CE, et al. Ibrutinib for the treatment of chronic graft vs host disease in pediatric hematopoietic stem cell transplant patients: A single center experience. Pediatr Transplant 2020; 24: e13692.
  • 26. Singhal S, Brondstetter T, Miklos DB, Tierney DK, Hsu J, Chhatwani L. Ibrutinib for Chronic Pulmonary Graft-Versus-Host-Disease after Progression on Prior Therapy. Blood (2019; 134(Suppl1): 4532
APA SARICI A, ERKURT M, KUKU I, Kaya E, BERBER I, Biçim S, Hidayet E, kaya a, BAHÇECİOĞLU Ö, Tanriverdi L, Ozkan G (2023). The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. , 216 - 220. 10.4274/imj.galenos.2023.98370
Chicago SARICI AHMET,ERKURT MEHMET ALI,KUKU IRFAN,Kaya Emin,BERBER Ilhami,Biçim Soykan,Hidayet Emine,kaya ahmet,BAHÇECİOĞLU ÖMER FARUK,Tanriverdi Lokman Hekim,Ozkan Gulkan The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. (2023): 216 - 220. 10.4274/imj.galenos.2023.98370
MLA SARICI AHMET,ERKURT MEHMET ALI,KUKU IRFAN,Kaya Emin,BERBER Ilhami,Biçim Soykan,Hidayet Emine,kaya ahmet,BAHÇECİOĞLU ÖMER FARUK,Tanriverdi Lokman Hekim,Ozkan Gulkan The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. , 2023, ss.216 - 220. 10.4274/imj.galenos.2023.98370
AMA SARICI A,ERKURT M,KUKU I,Kaya E,BERBER I,Biçim S,Hidayet E,kaya a,BAHÇECİOĞLU Ö,Tanriverdi L,Ozkan G The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. . 2023; 216 - 220. 10.4274/imj.galenos.2023.98370
Vancouver SARICI A,ERKURT M,KUKU I,Kaya E,BERBER I,Biçim S,Hidayet E,kaya a,BAHÇECİOĞLU Ö,Tanriverdi L,Ozkan G The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. . 2023; 216 - 220. 10.4274/imj.galenos.2023.98370
IEEE SARICI A,ERKURT M,KUKU I,Kaya E,BERBER I,Biçim S,Hidayet E,kaya a,BAHÇECİOĞLU Ö,Tanriverdi L,Ozkan G "The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience." , ss.216 - 220, 2023. 10.4274/imj.galenos.2023.98370
ISNAD SARICI, AHMET vd. "The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience". (2023), 216-220. https://doi.org/10.4274/imj.galenos.2023.98370
APA SARICI A, ERKURT M, KUKU I, Kaya E, BERBER I, Biçim S, Hidayet E, kaya a, BAHÇECİOĞLU Ö, Tanriverdi L, Ozkan G (2023). The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. İstanbul Medical Journal, 24(2), 216 - 220. 10.4274/imj.galenos.2023.98370
Chicago SARICI AHMET,ERKURT MEHMET ALI,KUKU IRFAN,Kaya Emin,BERBER Ilhami,Biçim Soykan,Hidayet Emine,kaya ahmet,BAHÇECİOĞLU ÖMER FARUK,Tanriverdi Lokman Hekim,Ozkan Gulkan The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. İstanbul Medical Journal 24, no.2 (2023): 216 - 220. 10.4274/imj.galenos.2023.98370
MLA SARICI AHMET,ERKURT MEHMET ALI,KUKU IRFAN,Kaya Emin,BERBER Ilhami,Biçim Soykan,Hidayet Emine,kaya ahmet,BAHÇECİOĞLU ÖMER FARUK,Tanriverdi Lokman Hekim,Ozkan Gulkan The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. İstanbul Medical Journal, vol.24, no.2, 2023, ss.216 - 220. 10.4274/imj.galenos.2023.98370
AMA SARICI A,ERKURT M,KUKU I,Kaya E,BERBER I,Biçim S,Hidayet E,kaya a,BAHÇECİOĞLU Ö,Tanriverdi L,Ozkan G The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. İstanbul Medical Journal. 2023; 24(2): 216 - 220. 10.4274/imj.galenos.2023.98370
Vancouver SARICI A,ERKURT M,KUKU I,Kaya E,BERBER I,Biçim S,Hidayet E,kaya a,BAHÇECİOĞLU Ö,Tanriverdi L,Ozkan G The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience. İstanbul Medical Journal. 2023; 24(2): 216 - 220. 10.4274/imj.galenos.2023.98370
IEEE SARICI A,ERKURT M,KUKU I,Kaya E,BERBER I,Biçim S,Hidayet E,kaya a,BAHÇECİOĞLU Ö,Tanriverdi L,Ozkan G "The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience." İstanbul Medical Journal, 24, ss.216 - 220, 2023. 10.4274/imj.galenos.2023.98370
ISNAD SARICI, AHMET vd. "The Experience of Ibrutinib in Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience". İstanbul Medical Journal 24/2 (2023), 216-220. https://doi.org/10.4274/imj.galenos.2023.98370